Coreline Soft, an artificial intelligence-based healthcare company, said Thursday it agreed to provide its solution that diagnoses chronic obstructive pulmonary disease (COPD) for the University of Leicester in the U.K.

Coreline Soft, a company specializing in medical artificial intelligence solutions, has agreed to provide its solution diagnosing chronic obstructive pulmonary disease (COPD) to the University of Leicester in the U.K.
Coreline Soft, a company specializing in medical artificial intelligence solutions, has agreed to provide its solution diagnosing chronic obstructive pulmonary disease (COPD) to the University of Leicester in the U.K.

The agreement is the latest addition to the company’s European project, following the lung cancer screening 4-In-The-Lung-Run (4ITLR) project funded by the European Union (EU) for six nations, including France, Spain, and Italy, and the Holistic implementation study Assessing a Northern German interdisciplinary lung cancer Screening Effort (HANSE) program, it said.

The solution introduced to the University of Leicester is AVIEW COPD, which diagnoses COPD that causes the fourth most death worldwide. AVIEW COPD automatically analyzes lung cancer, and it can screen for pulmonary emphysema, bronchial tubes, air capture, and blood vessels.

COPD is a chronic inflammatory lung disease that makes lungs stiff and difficult to breathe. About 1.2 million people in the U.K. have the disease, which is expected to surpass 300 million globally. COPD prevalence has continuously risen, increasing 44.2 percent from 1990 to 2015, placing as the seventh leading cause of death in Korea, too.

CorelineSoft explained that the high mortality caused by COPD is due to an excessive number of patients entering the chronic stage before receiving an early diagnosis.

Suppose a patient finds out COPD at stage 4. In that case, the five-year survival rate significantly drops to between 20 to 30 percent, similar to lung cancer. In addition, COPD is difficult to cure, like Covid-19 and asthma completely, the company said.

The World Health Organization (WHO) also selected COPD as one of the four major non-infectious diseases requiring intensive care along with cardiovascular diseases, cancer, and diabetes in 2011.

The medical and bio-industry in the U.K. has grown significantly over the past five years. The size is rapidly increasing as the government focused on science and research industries to lead the economy after leaving the EU.

The University of Leicester introduced AVIEW COPD to diagnose COPD as it can check people’s chest, including their lungs, and test-related diseases simultaneously.

National Taiwan University Hospital, People’s Hospital of Ningxia in China, University Hospital of Hokkaido, and the Catholic University of Leuven adopted Coreline Soft’s AVIEW COPD solution. 

The company is speeding up to expand its sales by establishing a European subsidiary in Frankfurt, Germany.

Copyright © KBR Unauthorized reproduction, redistribution prohibited